II
RPRX icon

IFM Investors’s Royalty Pharma RPRX Stock Holding History

IFM Investors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.95M Buy
124,013
+3,210
+3% +$167K 0.05% 334
2026
Q1 		$5.79M Buy
120,803
+3,819
+3% +$167K 0.05% 331
2025
Q4 		$4.52M Buy
+116,984
New +$4.46M 0.04% 379

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IFM Investors's RPRX Position: Q2 2026 in Review

IFM Investors increased its Royalty Pharma (RPRX) stake by 2.7% in Q2 2026, buying an estimated $167K and bringing the position to 124,013 shares worth $6.95M. The position accounts for 0.05% of the portfolio, ranked #334.

IFM Investors first reported a position in RPRX in Q4 2025 and has held it in 3 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • IFM Investors held 124,013 shares of Royalty Pharma worth $6.95M as of Q2 2026.
  • IFM Investors bought 3,210 Royalty Pharma shares in Q2 2026, an estimated $167K.
  • Royalty Pharma made up 0.05% of IFM Investors's portfolio in Q2 2026, its #334 holding.
  • IFM Investors first reported a position in Royalty Pharma in Q4 2025 and has held it in 3 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on IFM Investors's 13F filing for Q2 2026, filed 21 Jul 2026.